Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin Alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects With Symptomatic Left Ventricular Systolic Dysfunction and Anemia

NCT00358215 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00358215
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00358215 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin Alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects With Symptomatic Left Ventricular Systolic Dysfunction and Anemia
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Completed
Start date
June 1, 2006
Completion date
October 11, 2012
Enrollment
2,278 (actual)
Sites
754

Conditions

As the registry lists them; a condition with its own page is linked.

anemia, cardiovascular disease, congestive heart failure, heart failure, ventricular dysfunction